Hansen J A, Anasetti C, Beatty P G, Martin P J, Thomas E D
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Clin Transpl. 1989:105-14.
Allogeneic marrow transplantation from a normal donor provides potential life-saving therapy for a variety of inherited and acquired diseases of the hematopoietic system. Donor selection is a major issue, and most marrow transplants have been done only when an HLA-identical sibling donor has been available. Successful transplants can be done from partially HLA-matched relatives, but graft failure, graft rejection, and GvHD become increasingly serious complications as the number of HLA incompatibilities increase. More recently it has been shown that marrow transplants from HLA-identical unrelated donors can be successful. The recent development of a National Marrow Donor Program to recruit large numbers of HLA-typed volunteers and to facilitate the unrelated donor search process promises to make marrow transplants available to a growing number of patients.
来自正常供体的异基因骨髓移植为多种遗传性和后天性造血系统疾病提供了潜在的挽救生命的治疗方法。供体选择是一个主要问题，并且大多数骨髓移植仅在有 HLA 匹配的同胞供体时才进行。部分 HLA 匹配的亲属也可成功进行移植，但随着 HLA 不相容性数量的增加，移植失败、移植物排斥和移植物抗宿主病（GvHD）会成为越来越严重的并发症。最近有研究表明，来自 HLA 匹配的无关供体的骨髓移植也可以成功。最近国家骨髓供体计划的发展，旨在招募大量进行 HLA 分型的志愿者并促进无关供体搜索过程，有望使越来越多的患者能够接受骨髓移植。
